ID   HMGCL_HUMAN             Reviewed;         325 AA.
AC   P35914; B4DUP4; B7UCC6; D3Y5K7; Q6IBC0; Q96FP8;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   25-OCT-2002, sequence version 2.
DT   10-MAY-2017, entry version 170.
DE   RecName: Full=Hydroxymethylglutaryl-CoA lyase, mitochondrial;
DE            Short=HL;
DE            Short=HMG-CoA lyase;
DE            EC=4.1.3.4;
DE   AltName: Full=3-hydroxy-3-methylglutarate-CoA lyase;
DE   Flags: Precursor;
GN   Name=HMGCL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=8440722;
RA   Mitchell G.A., Robert M.-F., Hruz P.W., Wang S., Fontaine G.,
RA   Behnke C.E., Mende-Mueller L.M., Schappert K., Lee C., Gibson K.M.,
RA   Miziorko H.M.;
RT   "3-hydroxy-3-methylglutaryl coenzyme A lyase (HL). Cloning of human
RT   and chicken liver HL cDNAs and characterization of a mutation causing
RT   human HL deficiency.";
RL   J. Biol. Chem. 268:4376-4381(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Skeletal muscle, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 21-325 (ISOFORM 1).
RX   PubMed=8617516; DOI=10.1006/geno.1996.0164;
RA   Wang S.P., Robert M.-F., Gibson K.M., Wanders R.J.A., Mitchell G.A.;
RT   "3-hydroxy-3-methylglutaryl CoA lyase (HL): mouse and human HL gene
RT   (HMGCL) cloning and detection of large gene deletions in two unrelated
RT   HL-deficient patients.";
RL   Genomics 33:99-104(1996).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 60-277 (ISOFORMS 2 AND 3), ALTERNATIVE
RP   SPLICING, AND TISSUE SPECIFICITY.
RC   TISSUE=Skeletal muscle;
RX   PubMed=21952825; DOI=10.1007/s11033-011-1270-8;
RA   Puisac B., Ramos M., Arnedo M., Menao S., Gil-Rodriguez M.C.,
RA   Teresa-Rodrigo M.E., Pie A., de Karam J.C., Wesselink J.J.,
RA   Gimenez I., Ramos F.J., Casals N., Gomez-Puertas P., Hegardt F.G.,
RA   Pie J.;
RT   "Characterization of splice variants of the genes encoding human
RT   mitochondrial HMG-CoA lyase and HMG-CoA synthase, the main enzymes of
RT   the ketogenesis pathway.";
RL   Mol. Biol. Rep. 39:4777-4785(2012).
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=7527399;
RA   Ashmarina L.I., Rusnak N., Miziorko H.M., Mitchell G.A.;
RT   "3-Hydroxy-3-methylglutaryl-CoA lyase is present in mouse and human
RT   liver peroxisomes.";
RL   J. Biol. Chem. 269:31929-31932(1994).
RN   [11]
RP   FUNCTION.
RX   PubMed=8566388; DOI=10.1042/bst023489s;
RA   Holmes H.C., Burns S.P., Chalmers R.A., Bain M.S., Iles R.A.;
RT   "Ketogenic flux from lipids and leucine, assessment in 3-hydroxy-3-
RT   methylglutaryl CoA lyase deficiency.";
RL   Biochem. Soc. Trans. 23:489S-489S(1995).
RN   [12]
RP   SUBUNIT, SUBCELLULAR LOCATION, DISULFIDE BOND, AND MUTAGENESIS OF
RP   CYS-323.
RX   PubMed=12464283; DOI=10.1016/S0003-9861(02)00584-2;
RA   Tuinstra R.L., Burgner J.W. II, Miziorko H.M.;
RT   "Investigation of the oligomeric status of the peroxisomal isoform of
RT   human 3-hydroxy-3-methylglutaryl-CoA lyase.";
RL   Arch. Biochem. Biophys. 408:286-294(2002).
RN   [13]
RP   MUTAGENESIS OF GLU-37; ASP-42; GLU-72; ASP-204; HIS-233; GLU-279 AND
RP   ASP-280, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, AND ENZYME
RP   REGULATION.
RX   PubMed=12874287; DOI=10.1074/jbc.M304472200;
RA   Tuinstra R.L., Miziorko H.M.;
RT   "Investigation of conserved acidic residues in 3-hydroxy-3-
RT   methylglutaryl-CoA lyase: implications for human disease and for
RT   functional roles in a family of related proteins.";
RL   J. Biol. Chem. 278:37092-37098(2003).
RN   [14]
RP   MUTAGENESIS OF ARG-41; ASP-42 AND HIS-233, AND BIOPHYSICOCHEMICAL
RP   PROPERTIES.
RX   PubMed=15122894; DOI=10.1021/bi0499765;
RA   Tuinstra R.L., Wang C.-Z., Mitchell G.A., Miziorko H.M.;
RT   "Evaluation of 3-hydroxy-3-methylglutaryl-coenzyme A lyase arginine-41
RT   as a catalytic residue: use of acetyldithio-coenzyme A to monitor
RT   product enolization.";
RL   Biochemistry 43:5287-5295(2004).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-48, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF CYS-323.
RX   PubMed=22865860; DOI=10.1074/jbc.M112.393231;
RA   Montgomery C., Pei Z., Watkins P.A., Miziorko H.M.;
RT   "Identification and characterization of an extramitochondrial human 3-
RT   Hydroxy-3-methylglutaryl-CoA lyase.";
RL   J. Biol. Chem. 287:33227-33236(2012).
RN   [18]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=22847177; DOI=10.1194/jlr.M025700;
RA   Arnedo M., Menao S., Puisac B., Teresa-Rodrigo M.E.,
RA   Gil-Rodriguez M.C., Lopez-Vinas E., Gomez-Puertas P., Casals N.,
RA   Casale C.H., Hegardt F.G., Pie J.;
RT   "Characterization of a novel HMG-CoA Lyase enzyme with a dual location
RT   in endoplasmic reticulum and cytosol.";
RL   J. Lipid Res. 53:2046-2056(2012).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 28-325 IN COMPLEX WITH
RP   MAGNESIUM AND SUBSTRATE ANALOG, AND HOMODIMERIZATION.
RX   PubMed=16330550; DOI=10.1074/jbc.M506880200;
RA   Fu Z., Runquist J.A., Forouhar F., Hussain M., Hunt J.F.,
RA   Miziorko H.M., Kim J.J.;
RT   "Crystal structure of human 3-hydroxy-3-methylglutaryl-CoA Lyase:
RT   insights into catalysis and the molecular basis for
RT   hydroxymethylglutaric aciduria.";
RL   J. Biol. Chem. 281:7526-7532(2006).
RN   [23]
RP   VARIANT HMGCLD ARG-233.
RX   PubMed=8798725; DOI=10.1074/jbc.271.40.24604;
RA   Roberts J., Mitchell G.A., Miziorko H.M.;
RT   "Modeling of a mutation responsible for human 3-hydroxy-3-
RT   methylglutaryl-CoA lyase deficiency implicates histidine-233 as an
RT   active site residue.";
RL   J. Biol. Chem. 271:24604-24609(1996).
RN   [24]
RP   VARIANTS HMGCLD GLN-41; GLU-42; GLY-42 AND HIS-42.
RX   PubMed=9463337; DOI=10.1086/301730;
RA   Mitchell G.A., Ozand P.T., Robert M.-F., Ashmarina L., Roberts J.,
RA   Gibson K.M., Wanders R.J., Wang S., Chevalier I., Ploechl E.,
RA   Miziorko H.;
RT   "HMG CoA lyase deficiency: identification of five causal point
RT   mutations in codons 41 and 42, including a frequent Saudi Arabian
RT   mutation, R41Q.";
RL   Am. J. Hum. Genet. 62:295-300(1998).
RN   [25]
RP   VARIANTS HMGCLD ARG-233 AND PRO-263.
RX   PubMed=9784232; DOI=10.1006/abbi.1998.0788;
RA   Zapater N., Pie J., Lloberas J., Rolland M.O., Leroux B.,
RA   Vidailhet M., Divry P., Hegardt F.G., Casals N.;
RT   "Two missense point mutations in different alleles in the 3-hydroxy-3-
RT   methylglutaryl coenzyme A lyase gene produce 3-hydroxy-3-
RT   methylglutaric aciduria in a French patient.";
RL   Arch. Biochem. Biophys. 358:197-203(1998).
RN   [26]
RP   VARIANT HMGCLD LYS-279.
RX   PubMed=11129331; DOI=10.1007/s004390000363;
RA   Muroi J., Yorifuji T., Uematsu A., Shigematsu Y., Onigata K.,
RA   Maruyama H., Nobutoki T., Kitamura A., Nakahata T.;
RT   "Molecular and clinical analysis of Japanese patients with 3-hydroxy-
RT   3-methylglutaryl CoA lyase (HL) deficiency.";
RL   Hum. Genet. 107:320-326(2000).
RN   [27]
RP   VARIANTS HMGCLD ARG-75; TYR-201 AND ASN-204.
RX   PubMed=12746442; DOI=10.1074/jbc.M304276200;
RA   Casals N., Gomez-Puertas P., Pie J., Mir C., Roca R., Puisac B.,
RA   Aledo R., Clotet J., Menao S., Serra D., Asins G., Till J.,
RA   Elias-Jones A.C., Cresto J.C., Chamoles N.A., Abdenur J.E.,
RA   Mayatepek E., Besley G., Valencia A., Hegardt F.G.;
RT   "Structural (betaalpha)8 TIM barrel model of 3-hydroxy-3-
RT   methylglutaryl-coenzyme A lyase.";
RL   J. Biol. Chem. 278:29016-29023(2003).
RN   [28]
RP   VARIANT HMGCLD GLN-41.
RX   PubMed=17173698; DOI=10.1186/1471-2350-7-86;
RA   Al-Sayed M., Imtiaz F., Alsmadi O.A., Rashed M.S., Meyer B.F.;
RT   "Mutations underlying 3-hydroxy-3-methylglutaryl CoA lyase deficiency
RT   in the Saudi population.";
RL   BMC Med. Genet. 7:86-86(2006).
RN   [29]
RP   VARIANT HMGCLD GLU-203, AND CHARACTERIZATION OF VARIANT HMGCLD
RP   GLU-203.
RX   PubMed=16601870; DOI=10.1007/s10545-006-0138-x;
RA   Mir C., Lopez-Vinas E., Aledo R., Puisac B., Rizzo C.,
RA   Dionisi-Vici C., Deodato F., Pie J., Gomez-Puertas P., Hegardt F.G.,
RA   Casals N.;
RT   "A single-residue mutation, G203E, causes 3-hydroxy-3-methylglutaric
RT   aciduria by occluding the substrate channel in the 3D structural model
RT   of HMG-CoA lyase.";
RL   J. Inherit. Metab. Dis. 29:64-70(2006).
RN   [30]
RP   VARIANT HMGCLD ASN-48, AND CHARACTERIZATION OF VARIANT HMGCLD ASN-48.
RX   PubMed=17459752; DOI=10.1016/j.ymgme.2007.03.007;
RA   Carrasco P., Menao S., Lopez-Vinas E., Santpere G., Clotet J.,
RA   Sierra A.Y., Gratacos E., Puisac B., Gomez-Puertas P., Hegardt F.G.,
RA   Pie J., Casals N.;
RT   "C-terminal end and aminoacid Lys48 in HMG-CoA lyase are involved in
RT   substrate binding and enzyme activity.";
RL   Mol. Genet. Metab. 91:120-127(2007).
RN   [31]
RP   VARIANT HMGCLD GLN-165.
RX   PubMed=19036343; DOI=10.1016/j.cca.2008.11.004;
RA   Lin W.D., Wang C.H., Lai C.C., Tsai Y., Wu J.Y., Chen C.P., Tsai F.J.;
RT   "Molecular analysis of Taiwanese patients with 3-hydroxy-3-
RT   methylglutaryl CoA lyase deficiency.";
RL   Clin. Chim. Acta 401:33-36(2009).
RN   [32]
RP   VARIANTS HMGCLD LYS-37; GLY-42; PHE-142; TYR-174; SER-192; PHE-200 AND
RP   ARG-233, AND CHARACTERIZATION OF VARIANTS HMGCLD LYS-37; PHE-142;
RP   TYR-174; SER-192 AND PHE-200.
RX   PubMed=19177531; DOI=10.1002/humu.20966;
RA   Menao S., Lopez-Vinas E., Mir C., Puisac B., Gratacos E., Arnedo M.,
RA   Carrasco P., Moreno S., Ramos M., Gil M.C., Pie A., Ribes A.,
RA   Perez-Cerda C., Ugarte M., Clayton P.T., Korman S.H., Serra D.,
RA   Asins G., Ramos F.J., Gomez-Puertas P., Hegardt F.G., Casals N.,
RA   Pie J.;
RT   "Ten novel HMGCL mutations in 24 patients of different origin with 3-
RT   hydroxy-3-methyl-glutaric aciduria.";
RL   Hum. Mutat. 30:E520-E529(2009).
CC   -!- FUNCTION: Key enzyme in ketogenesis (ketone body formation).
CC       Terminal step in leucine catabolism. Ketone bodies (beta-
CC       hydroxybutyrate, acetoacetate and acetone) are essential as an
CC       alternative source of energy to glucose, as lipid precursors and
CC       as regulators of metabolism. {ECO:0000269|PubMed:22847177,
CC       ECO:0000269|PubMed:22865860, ECO:0000269|PubMed:8566388}.
CC   -!- CATALYTIC ACTIVITY: (S)-3-hydroxy-3-methylglutaryl-CoA = acetyl-
CC       CoA + acetoacetate. {ECO:0000255|PROSITE-ProRule:PRU10115,
CC       ECO:0000269|PubMed:22847177, ECO:0000269|PubMed:22865860}.
CC   -!- COFACTOR:
CC       Name=a divalent metal cation; Xref=ChEBI:CHEBI:60240;
CC         Evidence={ECO:0000269|PubMed:12874287};
CC   -!- ENZYME REGULATION: Stimulated by reducing agents such as
CC       dithiothreitol (DTT). {ECO:0000269|PubMed:12874287}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=200 uM for magnesium ion {ECO:0000269|PubMed:12874287,
CC         ECO:0000269|PubMed:15122894};
CC         KM=48 uM for HMG-CoA {ECO:0000269|PubMed:12874287,
CC         ECO:0000269|PubMed:15122894};
CC         Vmax=191 umol/min/mg enzyme {ECO:0000269|PubMed:12874287,
CC         ECO:0000269|PubMed:15122894};
CC   -!- PATHWAY: Metabolic intermediate metabolism; (S)-3-hydroxy-3-
CC       methylglutaryl-CoA degradation; acetoacetate from (S)-3-hydroxy-3-
CC       methylglutaryl-CoA: step 1/1.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Can also form homotetramers.
CC       {ECO:0000269|PubMed:12464283, ECO:0000269|PubMed:16330550}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix. Peroxisome.
CC       Note=Unprocessed form is peroxisomal.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P35914-1; Sequence=Displayed;
CC       Name=2; Synonyms=HMGCS2delta5,6;
CC         IsoId=P35914-2; Sequence=VSP_047444;
CC         Note=The transcript is not translated, but would result in a
CC         catalytically impaired product if it was.;
CC       Name=3; Synonyms=HMGCS2delta5,6,7;
CC         IsoId=P35914-3; Sequence=VSP_047444, VSP_043788;
CC         Note=Very low expression. The transcript is not translated, but
CC         would result in a catalytically inactive product if it was.;
CC   -!- TISSUE SPECIFICITY: Highest expression in liver. Expressed in
CC       pancreas, kidney, intestine, testis, fibroblasts and lymphoblasts.
CC       Very low expression in brain and skeletal muscle. The relative
CC       expression of isoform 2 (at mRNA level) is highest in heart (30%),
CC       skeletal muscle (22%), and brain (14%).
CC       {ECO:0000269|PubMed:21952825}.
CC   -!- DISEASE: 3-hydroxy-3-methylglutaryl-CoA lyase deficiency (HMGCLD)
CC       [MIM:246450]: An autosomal recessive disease affecting ketogenesis
CC       and L-leucine catabolism. The disease usually appears in the first
CC       year of life after a fasting period and its clinical acute
CC       symptoms include vomiting, seizures, metabolic acidosis,
CC       hypoketotic hypoglycemia and lethargy. These symptoms sometimes
CC       progress to coma, with fatal outcome in some cases.
CC       {ECO:0000269|PubMed:11129331, ECO:0000269|PubMed:12746442,
CC       ECO:0000269|PubMed:16601870, ECO:0000269|PubMed:17173698,
CC       ECO:0000269|PubMed:17459752, ECO:0000269|PubMed:19036343,
CC       ECO:0000269|PubMed:19177531, ECO:0000269|PubMed:8798725,
CC       ECO:0000269|PubMed:9463337, ECO:0000269|PubMed:9784232}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the HMG-CoA lyase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L07033; AAA92733.1; -; mRNA.
DR   EMBL; AK300733; BAG62406.1; -; mRNA.
DR   EMBL; AK313869; BAG36597.1; -; mRNA.
DR   EMBL; BT009792; AAP88794.1; -; mRNA.
DR   EMBL; CR456884; CAG33165.1; -; mRNA.
DR   EMBL; AL031295; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL590728; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471134; EAW95094.1; -; Genomic_DNA.
DR   EMBL; BC010570; AAH10570.1; -; mRNA.
DR   EMBL; AH003700; AAB19099.1; -; Genomic_DNA.
DR   EMBL; FJ472654; ACK58684.1; -; mRNA.
DR   EMBL; GU433941; ADD21697.1; -; mRNA.
DR   CCDS; CCDS243.1; -. [P35914-1]
DR   CCDS; CCDS53279.1; -. [P35914-2]
DR   PIR; A45470; A45470.
DR   RefSeq; NP_000182.2; NM_000191.2. [P35914-1]
DR   RefSeq; NP_001159531.1; NM_001166059.1. [P35914-2]
DR   UniGene; Hs.533444; -.
DR   PDB; 2CW6; X-ray; 2.10 A; A/B/C/D/E/F=28-325.
DR   PDB; 3MP3; X-ray; 2.40 A; A/B/C/D/E/F=28-325.
DR   PDB; 3MP4; X-ray; 2.20 A; A/B/C/D/E/F=28-325.
DR   PDB; 3MP5; X-ray; 2.25 A; A/B/C/D/E/F=28-325.
DR   PDBsum; 2CW6; -.
DR   PDBsum; 3MP3; -.
DR   PDBsum; 3MP4; -.
DR   PDBsum; 3MP5; -.
DR   ProteinModelPortal; P35914; -.
DR   SMR; P35914; -.
DR   BioGrid; 109398; 22.
DR   IntAct; P35914; 9.
DR   MINT; MINT-3014127; -.
DR   STRING; 9606.ENSP00000363614; -.
DR   DrugBank; DB04594; 3-hydroxyglutaric acid.
DR   SwissLipids; SLP:000001292; -. [P35914-1]
DR   iPTMnet; P35914; -.
DR   PhosphoSitePlus; P35914; -.
DR   BioMuta; HMGCL; -.
DR   DMDM; 24418852; -.
DR   EPD; P35914; -.
DR   PaxDb; P35914; -.
DR   PeptideAtlas; P35914; -.
DR   PRIDE; P35914; -.
DR   DNASU; 3155; -.
DR   Ensembl; ENST00000374490; ENSP00000363614; ENSG00000117305. [P35914-1]
DR   Ensembl; ENST00000436439; ENSP00000389281; ENSG00000117305. [P35914-2]
DR   GeneID; 3155; -.
DR   KEGG; hsa:3155; -.
DR   UCSC; uc001bib.4; human. [P35914-1]
DR   CTD; 3155; -.
DR   DisGeNET; 3155; -.
DR   GeneCards; HMGCL; -.
DR   HGNC; HGNC:5005; HMGCL.
DR   HPA; HPA004727; -.
DR   MalaCards; HMGCL; -.
DR   MIM; 246450; phenotype.
DR   MIM; 613898; gene.
DR   neXtProt; NX_P35914; -.
DR   OpenTargets; ENSG00000117305; -.
DR   Orphanet; 20; 3-hydroxy-3-methylglutaric aciduria.
DR   PharmGKB; PA29336; -.
DR   eggNOG; KOG2368; Eukaryota.
DR   eggNOG; COG0119; LUCA.
DR   GeneTree; ENSGT00390000017690; -.
DR   HOGENOM; HOG000219757; -.
DR   HOVERGEN; HBG064656; -.
DR   InParanoid; P35914; -.
DR   KO; K01640; -.
DR   OMA; EAFAQKN; -.
DR   OrthoDB; EOG091G0DA9; -.
DR   PhylomeDB; P35914; -.
DR   TreeFam; TF105363; -.
DR   BioCyc; MetaCyc:HS04116-MONOMER; -.
DR   BRENDA; 4.1.3.4; 2681.
DR   Reactome; R-HSA-77111; Synthesis of Ketone Bodies.
DR   SABIO-RK; P35914; -.
DR   UniPathway; UPA00896; UER00863.
DR   ChiTaRS; HMGCL; human.
DR   EvolutionaryTrace; P35914; -.
DR   GenomeRNAi; 3155; -.
DR   PRO; PR:P35914; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000117305; -.
DR   CleanEx; HS_HMGCL; -.
DR   ExpressionAtlas; P35914; baseline and differential.
DR   Genevisible; P35914; HS.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:Ensembl.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005777; C:peroxisome; IDA:UniProtKB.
DR   GO; GO:0031406; F:carboxylic acid binding; IEA:Ensembl.
DR   GO; GO:0000062; F:fatty-acyl-CoA binding; IEA:Ensembl.
DR   GO; GO:0004419; F:hydroxymethylglutaryl-CoA lyase activity; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IPI:UniProtKB.
DR   GO; GO:0006637; P:acyl-CoA metabolic process; IEA:Ensembl.
DR   GO; GO:0046951; P:ketone body biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006552; P:leucine catabolic process; TAS:BHF-UCL.
DR   GO; GO:0006629; P:lipid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0007005; P:mitochondrion organization; IEA:Ensembl.
DR   GO; GO:0051262; P:protein tetramerization; IDA:UniProtKB.
DR   GO; GO:0070542; P:response to fatty acid; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0042594; P:response to starvation; IEA:Ensembl.
DR   Gene3D; 3.20.20.70; -; 1.
DR   InterPro; IPR013785; Aldolase_TIM.
DR   InterPro; IPR030020; HL.
DR   InterPro; IPR000138; HMG_CoA_lyase_AS.
DR   InterPro; IPR000891; PYR_CT.
DR   PANTHER; PTHR42738:SF4; PTHR42738:SF4; 1.
DR   Pfam; PF00682; HMGL-like; 1.
DR   PROSITE; PS01062; HMG_COA_LYASE; 1.
DR   PROSITE; PS50991; PYR_CT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Disease mutation; Disulfide bond; Lyase; Metal-binding; Mitochondrion;
KW   Peroxisome; Reference proteome; Transit peptide.
FT   TRANSIT       1     27       Mitochondrion.
FT   CHAIN        28    325       Hydroxymethylglutaryl-CoA lyase,
FT                                mitochondrial.
FT                                /FTId=PRO_0000013478.
FT   DOMAIN       33    300       Pyruvate carboxyltransferase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01151}.
FT   MOTIF       323    325       Microbody targeting signal.
FT                                {ECO:0000255}.
FT   ACT_SITE    266    266       {ECO:0000255|PROSITE-ProRule:PRU10115}.
FT   METAL        42     42       Divalent metal cation.
FT   METAL       233    233       Divalent metal cation.
FT   METAL       235    235       Divalent metal cation.
FT   METAL       275    275       Divalent metal cation.
FT   BINDING      41     41       Substrate.
FT   MOD_RES      48     48       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      48     48       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P38060}.
FT   MOD_RES     111    111       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P38060}.
FT   MOD_RES     137    137       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P38060}.
FT   MOD_RES     137    137       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P38060}.
FT   MOD_RES     179    179       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P38060}.
FT   MOD_RES     179    179       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P38060}.
FT   MOD_RES     324    324       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P38060}.
FT   DISULFID    323    323       Interchain.
FT                                {ECO:0000269|PubMed:12464283}.
FT   VAR_SEQ     117    187       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:21952825}.
FT                                /FTId=VSP_047444.
FT   VAR_SEQ     188    250       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:21952825}.
FT                                /FTId=VSP_043788.
FT   VARIANT      37     37       E -> K (in HMGCLD; activity lower than 5%
FT                                respect to the wild-type).
FT                                {ECO:0000269|PubMed:19177531}.
FT                                /FTId=VAR_058440.
FT   VARIANT      41     41       R -> Q (in HMGCLD; loss of activity and
FT                                of proton exchange; dbSNP:rs121964997).
FT                                {ECO:0000269|PubMed:17173698,
FT                                ECO:0000269|PubMed:9463337}.
FT                                /FTId=VAR_003744.
FT   VARIANT      42     42       D -> E (in HMGCLD; reduced activity).
FT                                {ECO:0000269|PubMed:9463337}.
FT                                /FTId=VAR_003745.
FT   VARIANT      42     42       D -> G (in HMGCLD; loss of activity).
FT                                {ECO:0000269|PubMed:19177531,
FT                                ECO:0000269|PubMed:9463337}.
FT                                /FTId=VAR_003746.
FT   VARIANT      42     42       D -> H (in HMGCLD; loss of activity).
FT                                {ECO:0000269|PubMed:9463337}.
FT                                /FTId=VAR_003747.
FT   VARIANT      48     48       K -> N (in HMGCLD; abolishes almost all
FT                                enzymatic activity).
FT                                {ECO:0000269|PubMed:17459752}.
FT                                /FTId=VAR_058441.
FT   VARIANT      70     70       V -> L (in HMGCLD; dbSNP:rs121964996).
FT                                /FTId=VAR_003748.
FT   VARIANT      75     75       S -> R (in HMGCLD).
FT                                {ECO:0000269|PubMed:12746442}.
FT                                /FTId=VAR_058442.
FT   VARIANT     142    142       S -> F (in HMGCLD; activity lower than 5%
FT                                respect to the wild-type).
FT                                {ECO:0000269|PubMed:19177531}.
FT                                /FTId=VAR_058443.
FT   VARIANT     165    165       R -> Q (in HMGCLD; dbSNP:rs199587895).
FT                                {ECO:0000269|PubMed:19036343}.
FT                                /FTId=VAR_065453.
FT   VARIANT     174    174       C -> Y (in HMGCLD; activity lower than 5%
FT                                respect to the wild-type;
FT                                dbSNP:rs765475941).
FT                                {ECO:0000269|PubMed:19177531}.
FT                                /FTId=VAR_058444.
FT   VARIANT     192    192       F -> S (in HMGCLD; activity lower than 5%
FT                                respect to the wild-type).
FT                                {ECO:0000269|PubMed:19177531}.
FT                                /FTId=VAR_058445.
FT   VARIANT     200    200       I -> F (in HMGCLD; activity lower than 5%
FT                                respect to the wild-type).
FT                                {ECO:0000269|PubMed:19177531}.
FT                                /FTId=VAR_058446.
FT   VARIANT     201    201       S -> Y (in HMGCLD; dbSNP:rs760106433).
FT                                {ECO:0000269|PubMed:12746442}.
FT                                /FTId=VAR_058447.
FT   VARIANT     203    203       G -> E (in HMGCLD; complete loss of
FT                                activity). {ECO:0000269|PubMed:16601870}.
FT                                /FTId=VAR_058448.
FT   VARIANT     204    204       D -> N (in HMGCLD).
FT                                {ECO:0000269|PubMed:12746442}.
FT                                /FTId=VAR_058449.
FT   VARIANT     233    233       H -> R (in HMGCLD; loss of activity;
FT                                dbSNP:rs727503963).
FT                                {ECO:0000269|PubMed:19177531,
FT                                ECO:0000269|PubMed:8798725,
FT                                ECO:0000269|PubMed:9784232}.
FT                                /FTId=VAR_003749.
FT   VARIANT     263    263       L -> P (in HMGCLD).
FT                                {ECO:0000269|PubMed:9784232}.
FT                                /FTId=VAR_058450.
FT   VARIANT     279    279       E -> K (in HMGCLD; dbSNP:rs28934894).
FT                                {ECO:0000269|PubMed:11129331}.
FT                                /FTId=VAR_014202.
FT   MUTAGEN      37     37       E->D: Normal activity.
FT                                {ECO:0000269|PubMed:12874287}.
FT   MUTAGEN      41     41       R->M: Reduced activity, and loss of
FT                                proton exchange.
FT                                {ECO:0000269|PubMed:15122894}.
FT   MUTAGEN      42     42       D->A,N: Loss of activity, and reduced
FT                                proton exchange rate.
FT                                {ECO:0000269|PubMed:12874287,
FT                                ECO:0000269|PubMed:15122894}.
FT   MUTAGEN      72     72       E->A: Loss of activity, and reduced
FT                                affinity for metal cofactor and
FT                                substrate. {ECO:0000269|PubMed:12874287}.
FT   MUTAGEN     204    204       D->A: Reduced activity, and reduced
FT                                affinity for metal cofactor and
FT                                substrate. {ECO:0000269|PubMed:12874287}.
FT   MUTAGEN     233    233       H->A: Loss of activity, and reduced
FT                                proton exchange rate.
FT                                {ECO:0000269|PubMed:12874287,
FT                                ECO:0000269|PubMed:15122894}.
FT   MUTAGEN     266    266       C->A: Loss of activity.
FT   MUTAGEN     279    279       E->A: Reduced thermal stability, but
FT                                normal activity.
FT                                {ECO:0000269|PubMed:12874287}.
FT   MUTAGEN     280    280       D->A: Normal activity.
FT                                {ECO:0000269|PubMed:12874287}.
FT   MUTAGEN     323    323       C->S: Abolishes interchain
FT                                homodimerization. Exhibits no DTT
FT                                stimulated activity.
FT                                {ECO:0000269|PubMed:12464283,
FT                                ECO:0000269|PubMed:22865860}.
FT   CONFLICT    243    243       A -> T (in Ref. 1; AAA92733).
FT                                {ECO:0000305}.
FT   STRAND       34     37       {ECO:0000244|PDB:2CW6}.
FT   TURN         39     41       {ECO:0000244|PDB:2CW6}.
FT   HELIX        42     45       {ECO:0000244|PDB:2CW6}.
FT   HELIX        53     65       {ECO:0000244|PDB:2CW6}.
FT   STRAND       69     71       {ECO:0000244|PDB:2CW6}.
FT   TURN         79     81       {ECO:0000244|PDB:2CW6}.
FT   HELIX        83     85       {ECO:0000244|PDB:2CW6}.
FT   HELIX        88     94       {ECO:0000244|PDB:2CW6}.
FT   HELIX       110    118       {ECO:0000244|PDB:2CW6}.
FT   STRAND      122    130       {ECO:0000244|PDB:2CW6}.
FT   HELIX       132    139       {ECO:0000244|PDB:2CW6}.
FT   HELIX       143    159       {ECO:0000244|PDB:2CW6}.
FT   STRAND      163    169       {ECO:0000244|PDB:2CW6}.
FT   TURN        170    172       {ECO:0000244|PDB:2CW6}.
FT   TURN        175    177       {ECO:0000244|PDB:2CW6}.
FT   HELIX       182    194       {ECO:0000244|PDB:2CW6}.
FT   STRAND      198    204       {ECO:0000244|PDB:2CW6}.
FT   HELIX       211    224       {ECO:0000244|PDB:2CW6}.
FT   HELIX       227    229       {ECO:0000244|PDB:2CW6}.
FT   STRAND      230    235       {ECO:0000244|PDB:2CW6}.
FT   HELIX       241    250       {ECO:0000244|PDB:2CW6}.
FT   STRAND      255    259       {ECO:0000244|PDB:2CW6}.
FT   HELIX       278    288       {ECO:0000244|PDB:2CW6}.
FT   HELIX       296    309       {ECO:0000244|PDB:2CW6}.
FT   HELIX       317    322       {ECO:0000244|PDB:2CW6}.
SQ   SEQUENCE   325 AA;  34360 MW;  B82B2488A10D6980 CRC64;
     MAAMRKALPR RLVGLASLRA VSTSSMGTLP KRVKIVEVGP RDGLQNEKNI VSTPVKIKLI
     DMLSEAGLSV IETTSFVSPK WVPQMGDHTE VLKGIQKFPG INYPVLTPNL KGFEAAVAAG
     AKEVVIFGAA SELFTKKNIN CSIEESFQRF DAILKAAQSA NISVRGYVSC ALGCPYEGKI
     SPAKVAEVTK KFYSMGCYEI SLGDTIGVGT PGIMKDMLSA VMQEVPLAAL AVHCHDTYGQ
     ALANTLMALQ MGVSVVDSSV AGLGGCPYAQ GASGNLATED LVYMLEGLGI HTGVNLQKLL
     EAGNFICQAL NRKTSSKVAQ ATCKL
//
